Infections in Cancer Patients with Solid Tumors: A Review

Solid tumors

•Carcinomas

•Lymphomas



Solid tumors

- 1,685,210 new cases of cancer will be diagnosed in the United States in 2016
- more than 14 million new cases worldwide
- cancers of the breast, lungs and bronchus, prostate, colon and rectum, and urinary bladder being the most common

• leukemias 4% of new cases

Infections in Cancer Patients with Solid Tumors

- Infections in patients with solid tumors have not been studied as well as in patients with hematologic malignancies
- Most patients with solid tumors are not significantly immunosuppressed and do not experience prolonged periods of neutropenia
- Infections are the most common complications seen in cancer patients
- Result of the underlying malignancy and of the various modalities used for treatment

| Risk factor(s) ^a | Additional explanatory comments |
|--|---|
| Neutropenia | Chemotherapy, radiation therapy, bone marrow infiltration with tumor, drugs (e.g., |
| | ganciclovir) |
| Disruption of anatomic barriers (e.g., skin, mucosal surfaces) | Chemotherapy (mucositis), radiation therapy, vascular access catheters, urinary catheters, |
| | percutaneous endoscopic gastrostomy tubes and other medical devices, |
| | surgical/diagnostic procedures |
| Obstruction due to primary or metastatic tumor | Airways: post-obstructive pneumonia, lung abscess, empyema, fistula formation (e.g., |
| | broncho-pleural or trachea-esophogeal) |
| | Biliary tract: ascending cholangitis, hepatic and pancreatic abscess |
| | Bowel: bowel obstruction, necrosis, perforation, peritonitis, hemorrhage |
| | Urinary tract: urinary tract infection, renal abscess, prostatitis or prostatic abscess |
| Procedure and devices | Diagnostic/therapeutic surgery: surgical site infections, wound dehiscence, abscess |
| | formation |
| | Shunts: disseminated infection (bacteremia) shunt-related infections such as |
| | meningitis/ventriculitis, hepato-biliary infections, complicated urinary tract infections |
| | |
| | Prosthetic devices: infected prosthesis, osteomyelitis and/or septic arthritis, local abscess |
| | formation, disseminated infection |
| Miscellaneous factors | Age, nutritional status, prior antibiotic exposure, loss of gag reflex |

| Clinical syndrome | Comments |
|--|--|
| Post-obstructive pneumonia | Frequent in patients with primary or metastatic lung lesions. |
| | Sometimes the initial manifestation of malignancy. Complications |
| | include lung abscess, fistula formation, or empyema. Treatment |
| | failures common |
| Obstructive uropathy | Common in patients with genitourinary and prostatic tumors. |
| | Complicated urinary tract infections and multidrug-resistant |
| | organisms are frequent |
| Reactivation of viral infections | Hepatitis B virus and hepatitis C virus, usually following |
| | chemotherapy or immunosuppressive therapy. Screening for all |
| | patients scheduled to receive chemotherapy is recommended as is |
| | HBV prophylaxis for patients with HBV infection |
| Clostridium difficile associated disease | Multiple risk factors (antibiotics, chemotherapy, local anatomical |
| | factors). Recurrent infections/relapses common. Newer therapies |
| | (fidaxomicin, fecal microbiota transplantation) have been |
| | developed |
| Neutropenic enterocolitis | Associated with taxanes (docetaxel and paclitaxel), vinorelbine, |
| | and other agents producing severe mucositis |

Epidemiology of Infections in Cancer Patients with Solid Tumors

- Most infections in patients with solid tumors are caused by the individual patients' resident microflora
- The distribution of causative organisms mirrors the normal microflora at a particular site of infection
- Acquisition of nosocomial or healthcare-associated pathogens generally occurs several days after hospitalization
- The site of care has shifted to a great extent to clinics and out-patient oncology centers, wherein healthcare-associated infections are also commonplace
- Prolonged or multiple antibiotic exposure, which often occurs in solid tumor patients, leads to the selection of
 resistant organisms
- Geographic and local (institutional) differences in microbiology and susceptibility/resistance patterns are not
 infrequent and must always be taken into account when choosing empiric treatment regiments